down arrow

Cyclo Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Biotechnology
  • ISIN: US23254X2018
USD
0.72
0.01 (1.39%)

Mar 27

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.551.45
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Dec 2024)

FII

0.05%

Held by 7 FIIs

DII

95.12%

Held by 3 DIIs

Promoter

2.05%

How big is Cyclo Therapeutics, Inc.?

22-Jun-2025

As of Mar 27, Cyclo Therapeutics, Inc. has a market capitalization of 20.73 million, with net sales of 0.87 million and a net profit of -23.33 million over the last four quarters. Shareholder's funds are at -14.85 million, and total assets are 4.69 million as of Dec 24.

As of Mar 27, Cyclo Therapeutics, Inc. has a market capitalization of 20.73 million, categorizing it as a Micro Cap company.<BR><BR>As of Mar 27, the sum of Net Sales for the latest four quarters is 0.87 million, while the sum of Net Profit for the same period is -23.33 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at -14.85 million and Total Assets at 4.69 million.

Read More

What does Cyclo Therapeutics, Inc. do?

22-Jun-2025

Cyclo Therapeutics, Inc. is a micro-cap biotechnology company with recent net sales of $0 million and a net loss of $4 million. It has a market cap of $20.73 million and key metrics indicating it is currently loss-making with no dividend yield.

Overview: <BR>Cyclo Therapeutics, Inc. operates in the biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Dec 2024) <BR>Market-cap: USD 20.73 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.85 <BR>Return on Equity: 159.14% <BR>Price to Book: -1.40<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Biotechnology

stock-summary
Market cap

USD 21 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.85

stock-summary
Return on Equity

159.14%

stock-summary
Price to Book

-1.40

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2024)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.07%
0%
21.07%
6 Months
4.92%
0%
4.92%
1 Year
-49.61%
0%
-49.61%
2 Years
-20.8%
0%
-20.8%
3 Years
-74.72%
0%
-74.72%
4 Years
-91.99%
0%
-91.99%
5 Years
-95.23%
0%
-95.23%

Cyclo Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-2.72%
EBIT Growth (5y)
-208.12%
EBIT to Interest (avg)
-16.93
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.85
Sales to Capital Employed (avg)
-0.18
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.22%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.40
EV to EBIT
-1.30
EV to EBITDA
-1.30
EV to Capital Employed
-15.39
EV to Sales
33.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Bearish
Bearish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (2.78%)

Foreign Institutions

Held by 7 Foreign Institutions (0.05%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 50.00% vs 100.00% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 52.27% vs -46.67% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.20",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.70",
          "val2": "-8.30",
          "chgp": "19.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.50",
          "val2": "-1.50",
          "chgp": "266.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.20",
          "val2": "-8.80",
          "chgp": "52.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-20,871.00%",
          "val2": "-35,459.50%",
          "chgp": "1,458.85%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -18.18% vs -21.43% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -15.92% vs -29.68% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.90",
          "val2": "1.10",
          "chgp": "-18.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.70",
          "val2": "-20.00",
          "chgp": "-28.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.30",
          "val2": "-20.10",
          "chgp": "-15.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-29,249.90%",
          "val2": "-18,626.90%",
          "chgp": "-1,062.30%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQstock-summary
Dec'24
Sep'24
Change(%)
Net Sales
0.30
0.20
50.00%
Operating Profit (PBDIT) excl Other Income
-6.70
-8.30
19.28%
Interest
0.00
0.00
Exceptional Items
2.50
-1.50
266.67%
Consolidate Net Profit
-4.20
-8.80
52.27%
Operating Profit Margin (Excl OI)
-20,871.00%
-35,459.50%
1,458.85%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2024 is 50.00% vs 100.00% in Sep 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2024 is 52.27% vs -46.67% in Sep 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.90
1.10
-18.18%
Operating Profit (PBDIT) excl Other Income
-25.70
-20.00
-28.50%
Interest
0.00
0.00
Exceptional Items
0.30
0.00
Consolidate Net Profit
-23.30
-20.10
-15.92%
Operating Profit Margin (Excl OI)
-29,249.90%
-18,626.90%
-1,062.30%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -18.18% vs -21.43% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -15.92% vs -29.68% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cyclo Therapeutics, Inc. stock-summary
stock-summary
Cyclo Therapeutics, Inc.
Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."